Article Type
Changed
Tue, 04/24/2018 - 01:18

 

While patients may be newly exposed to opioids during medical and surgical hospitalization and the prescription of opioids at discharge is common,1-5 prescribers of opioids at discharge may not intend to initiate long-term opioid (LTO) use. By understanding the frequency of progression to LTO use, hospitalists can better balance postdischarge pain treatment and the risk for unintended LTO initiation.

Estimates of LTO use rates following hospital discharge in selected populations1,2,4-6 have varied depending on the population studied and the method of defining LTO use.7 Rates of LTO use following incident opioid prescription have not been directly compared at medical versus surgical discharge or compared with initiation in the ambulatory setting. We present the rates of LTO use following incident opioid exposure at surgical discharge and medical discharge and identify the factors associated with LTO use following surgical and medical discharge.

METHODS

Data Sources

Veterans Health Administration (VHA) data were obtained through the Austin Information Technology Center for fiscal years (FYs) 2003 through 2012 (Austin, Texas). Decision support system national data extracts were used to identify prescription-dispensing events, and inpatient and outpatient medical SAS data sets were used to identify diagnostic codes. The study was approved by the University of Iowa Institutional Review Board and the Iowa City Veterans Affairs (VA) Health Care System Research and Development Committee.

Patients

We included all patients with an outpatient opioid prescription during FY 2011 that was preceded by a 1-year opioid-free period.7 Patients with broadly accepted indications for LTO use (eg, metastatic cancer, palliative care, or opioid-dependence treatment) were excluded.7

Opioid Exposure

We included all outpatient prescription fills for noninjectable dosage forms of butorphanol, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, oxymorphone, pentazocine, and tramadol. Consistent with the Centers for Disease Control and Prevention and VA/Department of Defense guidelines, LTO use was defined conceptually as regular use for >90 days. Operationalizing this definition to pharmacy refill data was established by using a cabinet supply methodology,7 which allows for the construction of episodes of continuous medication therapy by estimating the medication supply available to a patient for each day during a defined period based on the pattern of observed refills. LTO use was defined as an episode of continuous opioid supply for >90 days and beginning within 30 days of the initial prescription. While some studies have defined LTO use based on onset within 1 year following surgery,5 the requirement for onset within 30 days of initiation was applied to more strongly tie the association of developing LTO use with the discharge event and minimize various forms of bias that are introduced with extended follow-up periods.

Clinical Characteristics

Patients were classified as being medical discharges, surgical discharges, or outpatient initiators. Patients with an opioid index date within 2 days following discharge were designated based on discharge bed section; additionally, if patients had a surgical bed section during hospitalization, they were assigned as surgical discharges. Demographic, diagnosis, and medication exposure variables that were previously associated with LTO use were selected.8,9 Substance use disorder, chronic pain, anxiety disorder, and depressive disorder were based on International Classification of Diseases, 9th Revision (ICD-9) codes in the preceding year. The use of concurrent benzodiazepines, skeletal muscle relaxants, and antidepressants were determined at opioid initiation.10 Rural or urban residence was assigned by using the Rural-Urban Commuting Area Codes system and mapped with the zip code of a veteran’s residence.11

Analysis

Bivariate and multivariable relationships were determined by using logistic regression. The multivariable model considered all pairwise interaction terms between inpatient service (surgery versus medicine) and each of the variables in the model. Statistically significant interaction terms (P < .05) were retained, and all others were omitted from the final model. The main effects for variables that were involved in a significant interaction term were not reported in the final multivariable model; instead, we created fully specified multivariable models for surgery service and medicine service and reported odds ratios (ORs) for the main effects. All analyses were conducted by using SAS version 9.4 (SAS Institute Inc, Cary, North Carolina).

 

 

RESULTS

During FY 2011, 43,027 patients received an incident opioid prescription at discharge from a VHA hospital, including 26,476 surgical discharges and 16,551 medical discharges. Discharged veterans differed on nearly all the examined characteristics (Table 1). A lower proportion of surgical patients used VA mental health services, had a substance use disorder, anxiety, or depression diagnosis, or had active benzodiazepine or antidepressant prescriptions. A higher proportion of surgical patients had a chronic pain diagnosis. At discharge, a larger proportion of surgical patients (62.7%) than medical patients (48.6%) received hydrocodone and daily doses of ≥45 mg per day of morphine equivalents (12.8% vs 10.2%). Medical patients were more likely to receive an initial supply of ≥30 days.

The rate of LTO initiation was higher in medical patients (15.2%) than in surgical patients (5.3%; OR = 3.18; 95% confidence interval [CI], 2.97-3.41; Table 2). For reference, the rate of subsequent LTO initiation among outpatients was 19.3% (93,076 of 483,472). LTO use was most common among patients ages 50 to 64 years. Relative to urban areas, LTO risk was higher among residents of small, rural areas (OR = 1.29; 95% CI, 1.14-1.47). The interaction between inpatient service and race (χ2 = 7.9; degrees of freedom = 2; P = .019) was significant; black race was associated with a reduced risk for LTO use in medicine service patients (OR = 0.77; 95% CI, 0.69-0.87) but not surgical patients (OR = 0.96; 95% CI, 0.83-1.13; Table 2).

Concurrent use of benzodiazepines, antidepressants, and muscle relaxants and chronic pain diagnosis (but not mental health clinic use and anxiety and depressive disorders) were associated with LTO use. Interactions with inpatient services were observed for substance use disorder diagnoses and prior nonopioid analgesic use; the magnitude of the association was higher among surgical service patients than in the medical patients model (Table 2).

Days’ supply was associated with LTO use in a dose-dependent fashion relative to the reference category of ≤7 days: OR of 1.24 (95% CI, 1.12-1.37) for 8 to 14 days; OR of 1.56 (95% CI, 1.39-1.76) for 15 to 29 days; and OR of 2.59 (95% CI, 2.35-2.86) for 30 days (Table 2). LTO risk was higher among patients with an estimated dose of ≥15 morphine equivalents per day (MED) compared with those with doses of <15 equivalents (OR = 1.11; 95% CI, 1.02-1.21); patients who received >45 MED were at the greatest risk (OR = 1.70; 95% CI, 1.49-1.94).

DISCUSSION

Our observed LTO use rate of 5.3% among surgical patients compares with rates of 0.12% to 1.41%5 and 5.9% to 6.5%12 in privately insured samples and 4.1% among discharges in a single US hospital that included both medical and surgical patients in the United States.1 The LTO use rate of 15.2% among medically discharged patients more closely resembles the rates found among outpatient initiators13 and lacks robust comparators.

The observation that subsequent LTO use occurs more frequently in discharged medical patients than surgical patients is consistent with the findings of Calcaterra et al.1 that among patients with no surgery versus surgery during hospitalization, opioid receipt at discharge resulted in a higher adjusted OR (7.24 for no surgery versus 3.40 for surgery) for chronic opioid use at 1 year. One explanation for this finding may be an artifact of cohort selection in the study design: patients with prior opioid use are excluded from the cohort, and prior use may be more common among surgical patients presenting for elective inpatient surgery for painful conditions. Previous work suggests that opioid use preoperatively is a robust predictor of postoperative use, and rates of LTO use are low among patients without preoperative opioid exposure.6

Demographic characteristics associated with persistent opioid receipt were similar to those previously reported.5,8,9 The inclusion of medication classes indicated in the treatment of mental health or pain conditions (ie, antidepressants, benzodiazepines, muscle relaxants, and nonopioid analgesics) resulted in diagnoses based on ICD-9 codes being no longer associated with LTO use. Severity or activity of illness, preferences regarding pharmacologic or nonpharmacologic treatment and undiagnosed or undocumented pain-comorbid conditions may all contribute to this finding. Future work studying opioid-related outcomes should include variables that reflect pharmacologic management of comorbid diagnoses in the cohort development or analytic design.

The strongest risk factors were potentially modifiable: days’ supply, dose, and concurrent medications. The measures of opioid quantity supplied are associated with subsequent ongoing use and are consistent with recent work based on prescription drug–monitoring data in a single state14 and in a nationally representative sample.15 That this relationship persists following hospital discharge, a scenario in which LTO use is unlikely to be initiated by a provider (who would be expected to subsequently titrate or monitor therapy), further supports the potential to curtail unintended LTO use through judicious early prescribing decisions.

We assessed only opioids that were supplied through a VA pharmacy, which may lead to the misclassification of patients as opioid naive for inclusion and an underestimation of the rate of opioid use following discharge. It is possible that differences in the rates of non-VA pharmacy use differ in medical and surgical populations in a nonrandom way. This study was performed in a large, integrated health system and may not be generalizable outside the VA system, where more discontinuities between hospital and ambulatory care may exist.

 

 

 

CONCLUSION

The initiation of LTO use at discharge is more common in veterans who are discharged from medical than surgical hospitalizations, likely reflecting differences in the patient population, pain conditions, and discharge prescribing decisions. While patient characteristics are associated with LTO use, the strongest associations are with increasing index dose and days’ supply; both represent potentially modifiable prescriber behaviors. These findings support policy changes and other efforts to minimize dose and days supplied when short-term use is intended as a means to address the current opioid epidemic.

Acknowledgments

The work reported here was supported by the Department of Veterans Affairs Office of Academic Affiliations and Office of Research and Development (Dr. Mosher and Dr. Hofmeyer), and Health Services Research and Development Service (HSR&D) through the Comprehensive Access and Delivery Research and Evaluation Center (CIN 13-412) and a Career Development Award (CDA 10-017; Dr. Lund).

Disclosures

The authors report no conflict of interest in regard to this study. The authors had full access to and take full responsibility for the integrity of the data. All analyses were conducted by using SAS version 9.2 (SAS Institute Inc, Cary, NC). This manuscript is not under review elsewhere, and there is no prior publication of the manuscript contents. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The study was approved by the University of Iowa Institutional Review Board and the Iowa City Healthcare System Research and Development Committee.

References

1. Calcaterra SL, Yamashita TE, Min SJ, Keniston A, Frank JW, Binswanger IA. Opioid Prescribing at Hospital Discharge Contributes to Chronic Opioid Use. J Gen Intern Med. 2016;31(5):478-485. PubMed
2. Raebel MA, Newcomer SR, Reifler LM, et al. Chronic use of opioid medications before and after bariatric surgery. JAMA. 2013;310(13):1369-1376. PubMed
3. Mosher HJ, Jiang L, Vaughan Sarrazin MS, Cram P, Kaboli PJ, Vander Weg MW. Prevalence and characteristics of hospitalized adults on chronic opioid therapy. J Hosp Med. 2014;9(2):82-87. PubMed
4. Holman JE, Stoddard GJ, Higgins TF. Rates of prescription opiate use before and after injury in patients with orthopaedic trauma and the risk factors for prolonged opiate use. J Bone Joint Surg Am. 2013;95(12):1075-1080.
5. Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period. JAMA Intern Med. 2016;176(9):1286-1293. PubMed
6. Goesling J, Moser SE, Zaidi B, et al. Trends and predictors of opioid use after total knee and total hip arthroplasty. Pain. 2016;157(6):1259-1265. PubMed
7. Mosher HJ, Richardson KK, Lund BC. The 1-Year Treatment Course of New Opioid Recipients in Veterans Health Administration. Pain Med. 2016. [Epub ahead of print]. PubMed
8. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and medicaid insurance plans: The TROUP Study. Pain. 2010;150(2):332-339. PubMed
9. Seal KH, Shi Y, Cohen G, et al. Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. JAMA. 2012;307(9):940-947. PubMed
10. Mosher HJ, Richardson KK, Lund BC. Sedative Prescriptions Are Common at Opioid Initiation: An Observational Study in the Veterans Health Administration. Pain Med. 2017. [Epub ahead of print]. PubMed
11. Lund BC, Abrams TE, Bernardy NC, Alexander B, Friedman MJ. Benzodiazepine prescribing variation and clinical uncertainty in treating posttraumatic stress disorder. Psychiatr Serv. 2013;64(1):21-27. PubMed
12. Brummett CM, Waljee JF, Goesling J, et al. New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. JAMA Surg. 2017;152(6):e170504. PubMed
13. Mellbye A, Karlstad O, Skurtveit S, Borchgrevink PC, Fredheim OM. The duration and course of opioid therapy in patients with chronic non-malignant pain. Acta Anaesthesiol Scand. 2016;60(1):128-137. PubMed
14. Deyo RA, Hallvik SE, Hildebran C, et al. Association Between Initial Opioid Prescribing Patterns and Subsequent Long-Term Use Among Opioid-Naive Patients: A Statewide Retrospective Cohort Study. J Gen Intern Med. 2017;32(1):21-27. PubMed
15. Shah A, Hayes CJ, Martin BC. Factors Influencing Long-Term Opioid Use Among Opioid Naive Patients: An Examination of Initial Prescription Characteristics and Pain Etiologies. J Pain. 2017;18(11):1374-1383. PubMed

Article PDF
Issue
Journal of Hospital Medicine 13(4)
Publications
Topics
Page Number
243-248
Sections
Article PDF
Article PDF

 

While patients may be newly exposed to opioids during medical and surgical hospitalization and the prescription of opioids at discharge is common,1-5 prescribers of opioids at discharge may not intend to initiate long-term opioid (LTO) use. By understanding the frequency of progression to LTO use, hospitalists can better balance postdischarge pain treatment and the risk for unintended LTO initiation.

Estimates of LTO use rates following hospital discharge in selected populations1,2,4-6 have varied depending on the population studied and the method of defining LTO use.7 Rates of LTO use following incident opioid prescription have not been directly compared at medical versus surgical discharge or compared with initiation in the ambulatory setting. We present the rates of LTO use following incident opioid exposure at surgical discharge and medical discharge and identify the factors associated with LTO use following surgical and medical discharge.

METHODS

Data Sources

Veterans Health Administration (VHA) data were obtained through the Austin Information Technology Center for fiscal years (FYs) 2003 through 2012 (Austin, Texas). Decision support system national data extracts were used to identify prescription-dispensing events, and inpatient and outpatient medical SAS data sets were used to identify diagnostic codes. The study was approved by the University of Iowa Institutional Review Board and the Iowa City Veterans Affairs (VA) Health Care System Research and Development Committee.

Patients

We included all patients with an outpatient opioid prescription during FY 2011 that was preceded by a 1-year opioid-free period.7 Patients with broadly accepted indications for LTO use (eg, metastatic cancer, palliative care, or opioid-dependence treatment) were excluded.7

Opioid Exposure

We included all outpatient prescription fills for noninjectable dosage forms of butorphanol, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, oxymorphone, pentazocine, and tramadol. Consistent with the Centers for Disease Control and Prevention and VA/Department of Defense guidelines, LTO use was defined conceptually as regular use for >90 days. Operationalizing this definition to pharmacy refill data was established by using a cabinet supply methodology,7 which allows for the construction of episodes of continuous medication therapy by estimating the medication supply available to a patient for each day during a defined period based on the pattern of observed refills. LTO use was defined as an episode of continuous opioid supply for >90 days and beginning within 30 days of the initial prescription. While some studies have defined LTO use based on onset within 1 year following surgery,5 the requirement for onset within 30 days of initiation was applied to more strongly tie the association of developing LTO use with the discharge event and minimize various forms of bias that are introduced with extended follow-up periods.

Clinical Characteristics

Patients were classified as being medical discharges, surgical discharges, or outpatient initiators. Patients with an opioid index date within 2 days following discharge were designated based on discharge bed section; additionally, if patients had a surgical bed section during hospitalization, they were assigned as surgical discharges. Demographic, diagnosis, and medication exposure variables that were previously associated with LTO use were selected.8,9 Substance use disorder, chronic pain, anxiety disorder, and depressive disorder were based on International Classification of Diseases, 9th Revision (ICD-9) codes in the preceding year. The use of concurrent benzodiazepines, skeletal muscle relaxants, and antidepressants were determined at opioid initiation.10 Rural or urban residence was assigned by using the Rural-Urban Commuting Area Codes system and mapped with the zip code of a veteran’s residence.11

Analysis

Bivariate and multivariable relationships were determined by using logistic regression. The multivariable model considered all pairwise interaction terms between inpatient service (surgery versus medicine) and each of the variables in the model. Statistically significant interaction terms (P < .05) were retained, and all others were omitted from the final model. The main effects for variables that were involved in a significant interaction term were not reported in the final multivariable model; instead, we created fully specified multivariable models for surgery service and medicine service and reported odds ratios (ORs) for the main effects. All analyses were conducted by using SAS version 9.4 (SAS Institute Inc, Cary, North Carolina).

 

 

RESULTS

During FY 2011, 43,027 patients received an incident opioid prescription at discharge from a VHA hospital, including 26,476 surgical discharges and 16,551 medical discharges. Discharged veterans differed on nearly all the examined characteristics (Table 1). A lower proportion of surgical patients used VA mental health services, had a substance use disorder, anxiety, or depression diagnosis, or had active benzodiazepine or antidepressant prescriptions. A higher proportion of surgical patients had a chronic pain diagnosis. At discharge, a larger proportion of surgical patients (62.7%) than medical patients (48.6%) received hydrocodone and daily doses of ≥45 mg per day of morphine equivalents (12.8% vs 10.2%). Medical patients were more likely to receive an initial supply of ≥30 days.

The rate of LTO initiation was higher in medical patients (15.2%) than in surgical patients (5.3%; OR = 3.18; 95% confidence interval [CI], 2.97-3.41; Table 2). For reference, the rate of subsequent LTO initiation among outpatients was 19.3% (93,076 of 483,472). LTO use was most common among patients ages 50 to 64 years. Relative to urban areas, LTO risk was higher among residents of small, rural areas (OR = 1.29; 95% CI, 1.14-1.47). The interaction between inpatient service and race (χ2 = 7.9; degrees of freedom = 2; P = .019) was significant; black race was associated with a reduced risk for LTO use in medicine service patients (OR = 0.77; 95% CI, 0.69-0.87) but not surgical patients (OR = 0.96; 95% CI, 0.83-1.13; Table 2).

Concurrent use of benzodiazepines, antidepressants, and muscle relaxants and chronic pain diagnosis (but not mental health clinic use and anxiety and depressive disorders) were associated with LTO use. Interactions with inpatient services were observed for substance use disorder diagnoses and prior nonopioid analgesic use; the magnitude of the association was higher among surgical service patients than in the medical patients model (Table 2).

Days’ supply was associated with LTO use in a dose-dependent fashion relative to the reference category of ≤7 days: OR of 1.24 (95% CI, 1.12-1.37) for 8 to 14 days; OR of 1.56 (95% CI, 1.39-1.76) for 15 to 29 days; and OR of 2.59 (95% CI, 2.35-2.86) for 30 days (Table 2). LTO risk was higher among patients with an estimated dose of ≥15 morphine equivalents per day (MED) compared with those with doses of <15 equivalents (OR = 1.11; 95% CI, 1.02-1.21); patients who received >45 MED were at the greatest risk (OR = 1.70; 95% CI, 1.49-1.94).

DISCUSSION

Our observed LTO use rate of 5.3% among surgical patients compares with rates of 0.12% to 1.41%5 and 5.9% to 6.5%12 in privately insured samples and 4.1% among discharges in a single US hospital that included both medical and surgical patients in the United States.1 The LTO use rate of 15.2% among medically discharged patients more closely resembles the rates found among outpatient initiators13 and lacks robust comparators.

The observation that subsequent LTO use occurs more frequently in discharged medical patients than surgical patients is consistent with the findings of Calcaterra et al.1 that among patients with no surgery versus surgery during hospitalization, opioid receipt at discharge resulted in a higher adjusted OR (7.24 for no surgery versus 3.40 for surgery) for chronic opioid use at 1 year. One explanation for this finding may be an artifact of cohort selection in the study design: patients with prior opioid use are excluded from the cohort, and prior use may be more common among surgical patients presenting for elective inpatient surgery for painful conditions. Previous work suggests that opioid use preoperatively is a robust predictor of postoperative use, and rates of LTO use are low among patients without preoperative opioid exposure.6

Demographic characteristics associated with persistent opioid receipt were similar to those previously reported.5,8,9 The inclusion of medication classes indicated in the treatment of mental health or pain conditions (ie, antidepressants, benzodiazepines, muscle relaxants, and nonopioid analgesics) resulted in diagnoses based on ICD-9 codes being no longer associated with LTO use. Severity or activity of illness, preferences regarding pharmacologic or nonpharmacologic treatment and undiagnosed or undocumented pain-comorbid conditions may all contribute to this finding. Future work studying opioid-related outcomes should include variables that reflect pharmacologic management of comorbid diagnoses in the cohort development or analytic design.

The strongest risk factors were potentially modifiable: days’ supply, dose, and concurrent medications. The measures of opioid quantity supplied are associated with subsequent ongoing use and are consistent with recent work based on prescription drug–monitoring data in a single state14 and in a nationally representative sample.15 That this relationship persists following hospital discharge, a scenario in which LTO use is unlikely to be initiated by a provider (who would be expected to subsequently titrate or monitor therapy), further supports the potential to curtail unintended LTO use through judicious early prescribing decisions.

We assessed only opioids that were supplied through a VA pharmacy, which may lead to the misclassification of patients as opioid naive for inclusion and an underestimation of the rate of opioid use following discharge. It is possible that differences in the rates of non-VA pharmacy use differ in medical and surgical populations in a nonrandom way. This study was performed in a large, integrated health system and may not be generalizable outside the VA system, where more discontinuities between hospital and ambulatory care may exist.

 

 

 

CONCLUSION

The initiation of LTO use at discharge is more common in veterans who are discharged from medical than surgical hospitalizations, likely reflecting differences in the patient population, pain conditions, and discharge prescribing decisions. While patient characteristics are associated with LTO use, the strongest associations are with increasing index dose and days’ supply; both represent potentially modifiable prescriber behaviors. These findings support policy changes and other efforts to minimize dose and days supplied when short-term use is intended as a means to address the current opioid epidemic.

Acknowledgments

The work reported here was supported by the Department of Veterans Affairs Office of Academic Affiliations and Office of Research and Development (Dr. Mosher and Dr. Hofmeyer), and Health Services Research and Development Service (HSR&D) through the Comprehensive Access and Delivery Research and Evaluation Center (CIN 13-412) and a Career Development Award (CDA 10-017; Dr. Lund).

Disclosures

The authors report no conflict of interest in regard to this study. The authors had full access to and take full responsibility for the integrity of the data. All analyses were conducted by using SAS version 9.2 (SAS Institute Inc, Cary, NC). This manuscript is not under review elsewhere, and there is no prior publication of the manuscript contents. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The study was approved by the University of Iowa Institutional Review Board and the Iowa City Healthcare System Research and Development Committee.

 

While patients may be newly exposed to opioids during medical and surgical hospitalization and the prescription of opioids at discharge is common,1-5 prescribers of opioids at discharge may not intend to initiate long-term opioid (LTO) use. By understanding the frequency of progression to LTO use, hospitalists can better balance postdischarge pain treatment and the risk for unintended LTO initiation.

Estimates of LTO use rates following hospital discharge in selected populations1,2,4-6 have varied depending on the population studied and the method of defining LTO use.7 Rates of LTO use following incident opioid prescription have not been directly compared at medical versus surgical discharge or compared with initiation in the ambulatory setting. We present the rates of LTO use following incident opioid exposure at surgical discharge and medical discharge and identify the factors associated with LTO use following surgical and medical discharge.

METHODS

Data Sources

Veterans Health Administration (VHA) data were obtained through the Austin Information Technology Center for fiscal years (FYs) 2003 through 2012 (Austin, Texas). Decision support system national data extracts were used to identify prescription-dispensing events, and inpatient and outpatient medical SAS data sets were used to identify diagnostic codes. The study was approved by the University of Iowa Institutional Review Board and the Iowa City Veterans Affairs (VA) Health Care System Research and Development Committee.

Patients

We included all patients with an outpatient opioid prescription during FY 2011 that was preceded by a 1-year opioid-free period.7 Patients with broadly accepted indications for LTO use (eg, metastatic cancer, palliative care, or opioid-dependence treatment) were excluded.7

Opioid Exposure

We included all outpatient prescription fills for noninjectable dosage forms of butorphanol, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, oxymorphone, pentazocine, and tramadol. Consistent with the Centers for Disease Control and Prevention and VA/Department of Defense guidelines, LTO use was defined conceptually as regular use for >90 days. Operationalizing this definition to pharmacy refill data was established by using a cabinet supply methodology,7 which allows for the construction of episodes of continuous medication therapy by estimating the medication supply available to a patient for each day during a defined period based on the pattern of observed refills. LTO use was defined as an episode of continuous opioid supply for >90 days and beginning within 30 days of the initial prescription. While some studies have defined LTO use based on onset within 1 year following surgery,5 the requirement for onset within 30 days of initiation was applied to more strongly tie the association of developing LTO use with the discharge event and minimize various forms of bias that are introduced with extended follow-up periods.

Clinical Characteristics

Patients were classified as being medical discharges, surgical discharges, or outpatient initiators. Patients with an opioid index date within 2 days following discharge were designated based on discharge bed section; additionally, if patients had a surgical bed section during hospitalization, they were assigned as surgical discharges. Demographic, diagnosis, and medication exposure variables that were previously associated with LTO use were selected.8,9 Substance use disorder, chronic pain, anxiety disorder, and depressive disorder were based on International Classification of Diseases, 9th Revision (ICD-9) codes in the preceding year. The use of concurrent benzodiazepines, skeletal muscle relaxants, and antidepressants were determined at opioid initiation.10 Rural or urban residence was assigned by using the Rural-Urban Commuting Area Codes system and mapped with the zip code of a veteran’s residence.11

Analysis

Bivariate and multivariable relationships were determined by using logistic regression. The multivariable model considered all pairwise interaction terms between inpatient service (surgery versus medicine) and each of the variables in the model. Statistically significant interaction terms (P < .05) were retained, and all others were omitted from the final model. The main effects for variables that were involved in a significant interaction term were not reported in the final multivariable model; instead, we created fully specified multivariable models for surgery service and medicine service and reported odds ratios (ORs) for the main effects. All analyses were conducted by using SAS version 9.4 (SAS Institute Inc, Cary, North Carolina).

 

 

RESULTS

During FY 2011, 43,027 patients received an incident opioid prescription at discharge from a VHA hospital, including 26,476 surgical discharges and 16,551 medical discharges. Discharged veterans differed on nearly all the examined characteristics (Table 1). A lower proportion of surgical patients used VA mental health services, had a substance use disorder, anxiety, or depression diagnosis, or had active benzodiazepine or antidepressant prescriptions. A higher proportion of surgical patients had a chronic pain diagnosis. At discharge, a larger proportion of surgical patients (62.7%) than medical patients (48.6%) received hydrocodone and daily doses of ≥45 mg per day of morphine equivalents (12.8% vs 10.2%). Medical patients were more likely to receive an initial supply of ≥30 days.

The rate of LTO initiation was higher in medical patients (15.2%) than in surgical patients (5.3%; OR = 3.18; 95% confidence interval [CI], 2.97-3.41; Table 2). For reference, the rate of subsequent LTO initiation among outpatients was 19.3% (93,076 of 483,472). LTO use was most common among patients ages 50 to 64 years. Relative to urban areas, LTO risk was higher among residents of small, rural areas (OR = 1.29; 95% CI, 1.14-1.47). The interaction between inpatient service and race (χ2 = 7.9; degrees of freedom = 2; P = .019) was significant; black race was associated with a reduced risk for LTO use in medicine service patients (OR = 0.77; 95% CI, 0.69-0.87) but not surgical patients (OR = 0.96; 95% CI, 0.83-1.13; Table 2).

Concurrent use of benzodiazepines, antidepressants, and muscle relaxants and chronic pain diagnosis (but not mental health clinic use and anxiety and depressive disorders) were associated with LTO use. Interactions with inpatient services were observed for substance use disorder diagnoses and prior nonopioid analgesic use; the magnitude of the association was higher among surgical service patients than in the medical patients model (Table 2).

Days’ supply was associated with LTO use in a dose-dependent fashion relative to the reference category of ≤7 days: OR of 1.24 (95% CI, 1.12-1.37) for 8 to 14 days; OR of 1.56 (95% CI, 1.39-1.76) for 15 to 29 days; and OR of 2.59 (95% CI, 2.35-2.86) for 30 days (Table 2). LTO risk was higher among patients with an estimated dose of ≥15 morphine equivalents per day (MED) compared with those with doses of <15 equivalents (OR = 1.11; 95% CI, 1.02-1.21); patients who received >45 MED were at the greatest risk (OR = 1.70; 95% CI, 1.49-1.94).

DISCUSSION

Our observed LTO use rate of 5.3% among surgical patients compares with rates of 0.12% to 1.41%5 and 5.9% to 6.5%12 in privately insured samples and 4.1% among discharges in a single US hospital that included both medical and surgical patients in the United States.1 The LTO use rate of 15.2% among medically discharged patients more closely resembles the rates found among outpatient initiators13 and lacks robust comparators.

The observation that subsequent LTO use occurs more frequently in discharged medical patients than surgical patients is consistent with the findings of Calcaterra et al.1 that among patients with no surgery versus surgery during hospitalization, opioid receipt at discharge resulted in a higher adjusted OR (7.24 for no surgery versus 3.40 for surgery) for chronic opioid use at 1 year. One explanation for this finding may be an artifact of cohort selection in the study design: patients with prior opioid use are excluded from the cohort, and prior use may be more common among surgical patients presenting for elective inpatient surgery for painful conditions. Previous work suggests that opioid use preoperatively is a robust predictor of postoperative use, and rates of LTO use are low among patients without preoperative opioid exposure.6

Demographic characteristics associated with persistent opioid receipt were similar to those previously reported.5,8,9 The inclusion of medication classes indicated in the treatment of mental health or pain conditions (ie, antidepressants, benzodiazepines, muscle relaxants, and nonopioid analgesics) resulted in diagnoses based on ICD-9 codes being no longer associated with LTO use. Severity or activity of illness, preferences regarding pharmacologic or nonpharmacologic treatment and undiagnosed or undocumented pain-comorbid conditions may all contribute to this finding. Future work studying opioid-related outcomes should include variables that reflect pharmacologic management of comorbid diagnoses in the cohort development or analytic design.

The strongest risk factors were potentially modifiable: days’ supply, dose, and concurrent medications. The measures of opioid quantity supplied are associated with subsequent ongoing use and are consistent with recent work based on prescription drug–monitoring data in a single state14 and in a nationally representative sample.15 That this relationship persists following hospital discharge, a scenario in which LTO use is unlikely to be initiated by a provider (who would be expected to subsequently titrate or monitor therapy), further supports the potential to curtail unintended LTO use through judicious early prescribing decisions.

We assessed only opioids that were supplied through a VA pharmacy, which may lead to the misclassification of patients as opioid naive for inclusion and an underestimation of the rate of opioid use following discharge. It is possible that differences in the rates of non-VA pharmacy use differ in medical and surgical populations in a nonrandom way. This study was performed in a large, integrated health system and may not be generalizable outside the VA system, where more discontinuities between hospital and ambulatory care may exist.

 

 

 

CONCLUSION

The initiation of LTO use at discharge is more common in veterans who are discharged from medical than surgical hospitalizations, likely reflecting differences in the patient population, pain conditions, and discharge prescribing decisions. While patient characteristics are associated with LTO use, the strongest associations are with increasing index dose and days’ supply; both represent potentially modifiable prescriber behaviors. These findings support policy changes and other efforts to minimize dose and days supplied when short-term use is intended as a means to address the current opioid epidemic.

Acknowledgments

The work reported here was supported by the Department of Veterans Affairs Office of Academic Affiliations and Office of Research and Development (Dr. Mosher and Dr. Hofmeyer), and Health Services Research and Development Service (HSR&D) through the Comprehensive Access and Delivery Research and Evaluation Center (CIN 13-412) and a Career Development Award (CDA 10-017; Dr. Lund).

Disclosures

The authors report no conflict of interest in regard to this study. The authors had full access to and take full responsibility for the integrity of the data. All analyses were conducted by using SAS version 9.2 (SAS Institute Inc, Cary, NC). This manuscript is not under review elsewhere, and there is no prior publication of the manuscript contents. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The study was approved by the University of Iowa Institutional Review Board and the Iowa City Healthcare System Research and Development Committee.

References

1. Calcaterra SL, Yamashita TE, Min SJ, Keniston A, Frank JW, Binswanger IA. Opioid Prescribing at Hospital Discharge Contributes to Chronic Opioid Use. J Gen Intern Med. 2016;31(5):478-485. PubMed
2. Raebel MA, Newcomer SR, Reifler LM, et al. Chronic use of opioid medications before and after bariatric surgery. JAMA. 2013;310(13):1369-1376. PubMed
3. Mosher HJ, Jiang L, Vaughan Sarrazin MS, Cram P, Kaboli PJ, Vander Weg MW. Prevalence and characteristics of hospitalized adults on chronic opioid therapy. J Hosp Med. 2014;9(2):82-87. PubMed
4. Holman JE, Stoddard GJ, Higgins TF. Rates of prescription opiate use before and after injury in patients with orthopaedic trauma and the risk factors for prolonged opiate use. J Bone Joint Surg Am. 2013;95(12):1075-1080.
5. Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period. JAMA Intern Med. 2016;176(9):1286-1293. PubMed
6. Goesling J, Moser SE, Zaidi B, et al. Trends and predictors of opioid use after total knee and total hip arthroplasty. Pain. 2016;157(6):1259-1265. PubMed
7. Mosher HJ, Richardson KK, Lund BC. The 1-Year Treatment Course of New Opioid Recipients in Veterans Health Administration. Pain Med. 2016. [Epub ahead of print]. PubMed
8. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and medicaid insurance plans: The TROUP Study. Pain. 2010;150(2):332-339. PubMed
9. Seal KH, Shi Y, Cohen G, et al. Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. JAMA. 2012;307(9):940-947. PubMed
10. Mosher HJ, Richardson KK, Lund BC. Sedative Prescriptions Are Common at Opioid Initiation: An Observational Study in the Veterans Health Administration. Pain Med. 2017. [Epub ahead of print]. PubMed
11. Lund BC, Abrams TE, Bernardy NC, Alexander B, Friedman MJ. Benzodiazepine prescribing variation and clinical uncertainty in treating posttraumatic stress disorder. Psychiatr Serv. 2013;64(1):21-27. PubMed
12. Brummett CM, Waljee JF, Goesling J, et al. New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. JAMA Surg. 2017;152(6):e170504. PubMed
13. Mellbye A, Karlstad O, Skurtveit S, Borchgrevink PC, Fredheim OM. The duration and course of opioid therapy in patients with chronic non-malignant pain. Acta Anaesthesiol Scand. 2016;60(1):128-137. PubMed
14. Deyo RA, Hallvik SE, Hildebran C, et al. Association Between Initial Opioid Prescribing Patterns and Subsequent Long-Term Use Among Opioid-Naive Patients: A Statewide Retrospective Cohort Study. J Gen Intern Med. 2017;32(1):21-27. PubMed
15. Shah A, Hayes CJ, Martin BC. Factors Influencing Long-Term Opioid Use Among Opioid Naive Patients: An Examination of Initial Prescription Characteristics and Pain Etiologies. J Pain. 2017;18(11):1374-1383. PubMed

References

1. Calcaterra SL, Yamashita TE, Min SJ, Keniston A, Frank JW, Binswanger IA. Opioid Prescribing at Hospital Discharge Contributes to Chronic Opioid Use. J Gen Intern Med. 2016;31(5):478-485. PubMed
2. Raebel MA, Newcomer SR, Reifler LM, et al. Chronic use of opioid medications before and after bariatric surgery. JAMA. 2013;310(13):1369-1376. PubMed
3. Mosher HJ, Jiang L, Vaughan Sarrazin MS, Cram P, Kaboli PJ, Vander Weg MW. Prevalence and characteristics of hospitalized adults on chronic opioid therapy. J Hosp Med. 2014;9(2):82-87. PubMed
4. Holman JE, Stoddard GJ, Higgins TF. Rates of prescription opiate use before and after injury in patients with orthopaedic trauma and the risk factors for prolonged opiate use. J Bone Joint Surg Am. 2013;95(12):1075-1080.
5. Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period. JAMA Intern Med. 2016;176(9):1286-1293. PubMed
6. Goesling J, Moser SE, Zaidi B, et al. Trends and predictors of opioid use after total knee and total hip arthroplasty. Pain. 2016;157(6):1259-1265. PubMed
7. Mosher HJ, Richardson KK, Lund BC. The 1-Year Treatment Course of New Opioid Recipients in Veterans Health Administration. Pain Med. 2016. [Epub ahead of print]. PubMed
8. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and medicaid insurance plans: The TROUP Study. Pain. 2010;150(2):332-339. PubMed
9. Seal KH, Shi Y, Cohen G, et al. Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. JAMA. 2012;307(9):940-947. PubMed
10. Mosher HJ, Richardson KK, Lund BC. Sedative Prescriptions Are Common at Opioid Initiation: An Observational Study in the Veterans Health Administration. Pain Med. 2017. [Epub ahead of print]. PubMed
11. Lund BC, Abrams TE, Bernardy NC, Alexander B, Friedman MJ. Benzodiazepine prescribing variation and clinical uncertainty in treating posttraumatic stress disorder. Psychiatr Serv. 2013;64(1):21-27. PubMed
12. Brummett CM, Waljee JF, Goesling J, et al. New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. JAMA Surg. 2017;152(6):e170504. PubMed
13. Mellbye A, Karlstad O, Skurtveit S, Borchgrevink PC, Fredheim OM. The duration and course of opioid therapy in patients with chronic non-malignant pain. Acta Anaesthesiol Scand. 2016;60(1):128-137. PubMed
14. Deyo RA, Hallvik SE, Hildebran C, et al. Association Between Initial Opioid Prescribing Patterns and Subsequent Long-Term Use Among Opioid-Naive Patients: A Statewide Retrospective Cohort Study. J Gen Intern Med. 2017;32(1):21-27. PubMed
15. Shah A, Hayes CJ, Martin BC. Factors Influencing Long-Term Opioid Use Among Opioid Naive Patients: An Examination of Initial Prescription Characteristics and Pain Etiologies. J Pain. 2017;18(11):1374-1383. PubMed

Issue
Journal of Hospital Medicine 13(4)
Issue
Journal of Hospital Medicine 13(4)
Page Number
243-248
Page Number
243-248
Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Correspondence Location
Hilary J. Mosher, MFA, MD, Iowa City VA Health Care System, 601 Highway 6 West, Mailstop 111, Iowa City, IA 52246-2208; Telephone: 319-338-0581 extension 7723; Fax: 319-887-4932; E-mail: hilary.mosher@va.gov
Content Gating
Gated (full article locked unless allowed per User)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 04/24/2018 - 00:00
Use ProPublica
Gating Strategy
First Peek Free
Article PDF Media